Skadden is advising Otsuka Pharmaceutical Co., Ltd. on its $1.225 billion acquisition of Transcend Therapeutics, Inc., inclusive of earnout payments. The Skadden team includes Mitsuhiro Kamiya, Michael Mies, Ken Kumayama, David Schwartz and Avia Dunn.
Skadden, Arps, Slate, Meagher & Flom LLP and Affiliates